Intensified & Continuous Bioprocessing
Continuous Innovation. Intensified Results.
8/11/2026 - August 12, 2026 ALL TIMES EDT
The Intensified & Continuous Bioprocessing conference brings together the industry’s leading innovators to explore the cutting edge of high-efficiency, next-generation biomanufacturing. With deep dives into end-to-end continuous platforms, advanced upstream intensification, continuous chromatography, novel midstream technologies, real-time process control and predictive modeling strategies, this event showcases how companies are accelerating development, reducing costs, and enabling more robust production. Join industry experts leading the continuous innovations that will boost productivity and excellence in next-generation bioprocessing.
Preliminary Agenda

Session Block

INTENSIFIED UPSTREAM PROCESSING FOR NOVEL MODALITIES

KEYNOTE PRESENTATION: Intensified Fed-Batch and Continuous CHO Cell Cultures for Biologics Manufacturing

Photo of Weichang Zhou, PhD, CTO, MediLink Therapeutics , CTO , MediLink Therapeutics
Weichang Zhou, PhD, CTO, MediLink Therapeutics , CTO , MediLink Therapeutics

Stable Perfusion Cultures of Mammalian Cells for Integrative Continuous Bioprocessing

Photo of Duk Jae Oh, PhD, Professor, Integrative Bioscience & Biotechnology, Sejong University , Prof , Integrative Bioscience & Biotechnology , Sejong University
Duk Jae Oh, PhD, Professor, Integrative Bioscience & Biotechnology, Sejong University , Prof , Integrative Bioscience & Biotechnology , Sejong University
Photo of Hussain Nuruddin Dahodwala, PhD, IBBR NIST-UMD , Professor , Upstream process development , IBBR-NIST
Hussain Nuruddin Dahodwala, PhD, IBBR NIST-UMD , Professor , Upstream process development , IBBR-NIST
Photo of Prashant Mainali, PhD, Scientist, Microbial Cell Bioprocessing, A STAR (Agency of Science, Technology and Research) , Scientist , Microbial Cell Bioprocessing , A STAR (Agency of Science, Technology and Research)
Prashant Mainali, PhD, Scientist, Microbial Cell Bioprocessing, A STAR (Agency of Science, Technology and Research) , Scientist , Microbial Cell Bioprocessing , A STAR (Agency of Science, Technology and Research)

This presentation will compare the production of Fibroblast Growth Factor-2 (FGF2) using two microbial hosts with distinct bioprocess characteristics, necessitating different strategies for process optimization. This talk will provide the audience with a practical framework for selecting and optimizing microbial hosts for growth factor production based on their intrinsic biological and bioprocess characteristics. The presentation will also demonstrate how kinetic modeling can be directly translated into operational decisions for continuous and perfusion cultures, and how advanced fermentation strategies such as chemostat-filtration coupling and cascade fermentation can be used to overcome metabolic burden and stability limitations. These concepts will be broadly applicable to the continuous manufacturing of recombinant proteins for biopharmaceutical, cultivated meat, and serum-free media applications.

CONTINUOUS AND INTENSIFIED DOWNSTREAM

KEYNOTE PRESENTATION: From Batches to Flow: Transforming Downstream Processing into a Continuous Enterprise

Photo of Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University , Prof & Head, Biotechnology , BOKU University , University of Natural Resources & Life Sciences
Alois Jungbauer, PhD, Professor & Head, Biotechnology, Institute of Bioprocess Science and Engineering, BOKU University , Prof & Head, Biotechnology , BOKU University , University of Natural Resources & Life Sciences

Continuous bioprocessing offers transformative potential but faces persistent scale-down and integration challenges. In downstream processing, maintaining stable micro- to milliliter-per-minute flow rates is essential, and fully continuous solid–liquid separation remains a bottleneck. Hollow-fiber based two-stage filtration provides a practical scale-down strategy, while continuous precipitation and flocculation represent powerful alternatives when robust separation is ensured. At manufacturing scale, fluid and buffer logistics dominate. Emerging soft-sensor concepts for online CQAs enable long-running, integrated processes, positioning continuous biomanufacturing as a cornerstone for future carbon-neutral pharmaceutical production.

Optimizing Throughput, Mass Indices, and Cost of Goods in Continuous, Precipitation-Based mAb Downstream Processing

Photo of Todd M. Przybycien, PhD, Professor and Head, Chemical and Biological Engineering, Rensselaer Polytechnic Institute , Professor and Head , Chemical & Biological Engineering , Rensselaer Polytechnic Institute
Todd M. Przybycien, PhD, Professor and Head, Chemical and Biological Engineering, Rensselaer Polytechnic Institute , Professor and Head , Chemical & Biological Engineering , Rensselaer Polytechnic Institute

Becky Chmielowski, PhD, Principal Scientist, Merck & Co. , Senior Principal Scientist , Merck & Co

INNOVATIONS IN FACILITY DESIGN, AI, AND AUTOMATION FOR CONTINUOUS/INTENSIFIED PROCESSES

How “Flexible” Platform Design Paradigm Enables Innovation to Support Highly Intensified-Processes

Photo of Jonathan K. Romero, PhD, Distinguished Scientist, BioProcess Research & Development, Merck Research Laboratories , Distinguished Scientist , BioProcess Research & Development , Merck Research Laboratories
Jonathan K. Romero, PhD, Distinguished Scientist, BioProcess Research & Development, Merck Research Laboratories , Distinguished Scientist , BioProcess Research & Development , Merck Research Laboratories

Ana DiLillo, Assoc Specialist, Clinical Biologics, AstraZeneca , Assoc Specialist , Clinical Biologics , AstraZeneca

Photo of Juergen Mairhofer, CEO & Co-Founder, enGenes Biotech GmbH , CEO & CoFounder , enGenes Biotech GmbH
Juergen Mairhofer, CEO & Co-Founder, enGenes Biotech GmbH , CEO & CoFounder , enGenes Biotech GmbH
Photo of William Whitford, Founder, Oamaru BioSystems , Founder , Oamaru BioSystems , Oamaru BioSystems
William Whitford, Founder, Oamaru BioSystems , Founder , Oamaru BioSystems , Oamaru BioSystems

A digital shadow is a near–real-time, data-driven virtual representation of a bioreactor and its process. An AI-augmented digital shadow (AIS) accelerates process intensification by integrating multivariate data with machine-learning and hybrid mechanistic models to identify actionable parameters and nonlinear interactions. AIS enables what-if simulation of equipment configurations, CPP strategies, and feeding profiles before execution. It can infer hard-to-measure state variables, assess scale equivalence, and support model-predictive and adaptive control by recommending near-optimal setpoints. By mapping high-dimensional parameter space and ranking limiting phenomena, AIS strengthens design-space definition, regulatory justification, first-time-right success, and manufacturing robustness.


For more details on the conference, please contact:

Mimi Langley

Executive Director, Conferences

Cambridge Healthtech Institute

Email: mlangley@healthtech.com

 

For sponsorship information, please contact:

 

Companies A-K

Phillip Zakim-Yacouby

Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-247-1815

Email: philzy@cambridgeinnovationinstitute.com

 

Companies L-Z

Aimee Croke

Senior Business Development Manager

Cambridge Healthtech Institute

Phone: (+1) 781-292-0777

Email: acroke@cambridgeinnovationinstitute.com